You are correct—carvedilol is NOT cardioselective
Carvedilol is a nonselective β-blocker that blocks both β1 and β2 adrenergic receptors, plus it has α1-blocking activity. This distinguishes it fundamentally from cardioselective agents like metoprolol, bisoprolol, and atenolol 1.
Key Pharmacologic Properties
Carvedilol's mechanism involves:
- Nonselective β-blockade: Blocks both β1 (cardiac) and β2 (pulmonary/vascular) receptors at approximately equal potency 1
- α1-blockade: Provides vasodilation, which differentiates it from pure β-blockers 1
- No intrinsic sympathomimetic activity 1
The FDA label explicitly states carvedilol is "a nonselective β-adrenergic blocking agent with α1-blocking activity" 1.
Clinical Classification in Guidelines
Multiple authoritative guidelines consistently classify carvedilol as nonselective or combined α/β-blocker:
- 2017 ACC/AHA Hypertension Guidelines categorize carvedilol under "Beta blockers—combined alpha- and beta-receptor" rather than with cardioselective agents like bisoprolol or metoprolol 2, 3, 4
- 2016 ESC Atrial Fibrillation Guidelines note that in asthma cases, guidelines "recommend beta-1 selective agents (avoid carvedilol)" 5—explicitly acknowledging its lack of cardioselectivity
- 2011 NICE Heart Failure Guidelines describe carvedilol as "the nonselective β-blocker" when comparing it to "selective β-blockers, such as bisoprolol and metoprolol" 6
Why This Matters Clinically
In Reactive Airway Disease
Carvedilol should be avoided in patients with asthma or severe bronchospastic disease because its β2-blockade can precipitate bronchospasm 5, 2. The 2017 ACC/AHA guidelines specifically state: "Bronchospasm is rare—in cases of asthma, recommend beta-1 selective agents (avoid carvedilol)" 2.
If a β-blocker is needed in patients with mild COPD or reactive airways, use cardioselective agents (bisoprolol, metoprolol, or atenolol) at low doses 7.
In Heart Failure
Despite being nonselective, carvedilol is preferred in HFrEF due to its additional α1-blockade and potential pleiotropic effects 2, 3, 4. The 2011 NICE guidelines note that while carvedilol showed lower mortality versus metoprolol tartrate in one trial, this likely reflected the short-acting formulation used rather than selectivity differences—bisoprolol and metoprolol succinate (both selective) show similar mortality benefits 6.
Hemodynamic Differences
The nonselective nature combined with α1-blockade produces distinct acute hemodynamics:
- Carvedilol: No change or slight decrease in cardiac output, decreased peripheral resistance, risk of postural hypotension 8, 9
- Selective β-blockers: Reduced cardiac output, tendency toward increased pulmonary wedge pressure initially 8
Common Pitfall
Do not assume all β-blockers used in heart failure are cardioselective. While bisoprolol and metoprolol are selective, carvedilol is not. This matters for:
- Patient selection (avoid in asthma)
- Side effect profile (more dizziness/hypotension with carvedilol due to α-blockade 6)
- Dosing considerations (carvedilol requires twice-daily dosing; selective agents often once-daily) 2, 3
The evidence-based β-blockers for heart failure include both selective (bisoprolol, metoprolol succinate) and nonselective (carvedilol, nebivolol) agents 6, 10, 6.